Profil
Mark Sumeray is currently a Director at Metys Pharmaceuticals AG.
Previously, he worked as the Chief Medical Officer at Aegerion Pharmaceuticals, Inc. from 2011 to 2016 and at Amryt Pharma Holdings Ltd. from 2016 to 2022.
Dr. Sumeray received his undergraduate and doctorate degrees from University College London.
Aktive Positionen von Mark Sumeray
| Unternehmen | Position | Beginn |
|---|---|---|
Metys Pharmaceuticals AG
Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Mark Sumeray
| Unternehmen | Position | Ende |
|---|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for patients with rare and orphan diseases | Technik-/Wissenschafts-/F&E-Leiter | 27.06.2022 |
| AEGERION PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 28.01.2016 |
Ausbildung von Mark Sumeray
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for patients with rare and orphan diseases | Health Technology |
Metys Pharmaceuticals AG
Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
















